Systemic Inflammation During Recanalization of Cerebral Arterial Occlusion

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04731584

Acronym

CONVASC-I

Enrollment

Registered

2021-02-01

Start date

2021-04-07

Completion date

2021-06-12

Last updated

2023-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke, Systemic Infection

Brief summary

Strokes management, secondary to proximal arterial occlusion, by endovascular thrombectomy (TM) is now well established. The immuno-inflammatory events of reperfusion after TM are discussed. Systemic inflammation is a major factor suggested to explain the limited recovery of the ischemic parenchyma. Understanding these phenomena is necessary before developing an immunomodulatory strategy.

Interventions

BIOLOGICALBlood sample

Patients from 2 groups will undergo blood sample (during a blood sample for there care) and inflammation parameters will be measure the day of the stroke

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

GROUP AVC : Inclusion Criteria: * Adults patient (s) * Ischemic stroke by occlusion of a middle cerebral artery (proximal portion M1) * Initial diagnostic MRI infusion * TM with complete reperfusion (TICI 2b, 2c or 3) * TM performed under local anesthesia +/- anxiolysis, or sedation including propofol * mRS prior to stroke \<2 * Barthel index \<90 * Included in the HIBISCUS cohort * Patient who was informed and did not object to participating in the study OR included through the emergency procedure then collection of his non-objection or that of his trusted person as soon as possible

Exclusion criteria

* NIHSS awareness score\> or = 2 * Haemorrhagic complication before thrombectomy * Pregnant woman * Multiple vascular occlusions * Occlusions of posterior or anterior cerebral territories other than M1 * Protected major * TM performed under general anesthesia * Other vital failure than neurological failure GROUP CONTROL : Inclusion Criteria: * Adults patient (s) * mRS \<2 * Barthel index \<90 * Requiring diagnostic arteriography for routine check-up of a cerebrovascular malformation * Patient who was informed and did not object to participating in the study

Design outcomes

Primary

Measure	Time frame	Description
Inflammation parameters description	1 day	Inflammatory parameters such as CRP, IL-6, IL-10, HLA-DR, TNF-alpha, polymorphonuclear chemotaxis, CD-4, T-lymphocytes will be measure in blood sample

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026